Enteral Medicine Straw Market Size to Reach USD 5.8 Million by 2034 | Trends & Forecasts According to a newly published market research report by 24LifeSciences, global enteral medicine straw market was valued at USD 4.2 million in 2024 and is projected to reach USD 5.8 million by 2032, growing at a compound annual growth rate (CAGR) of 4.1% during the forecast period 2025–2032. Enteral medicine straws are specialized medical devices designed for the safe and accurate oral administration of liquid or powdered medication to patients with dysphagia or those reliant on enteral feeding tubes. These single-use, calibrated straws are critical for ensuring precise dosing, preventing tube occlusions, and minimizing contamination risks in both clinical and homecare settings. Their role in facilitating effective medication delivery for vulnerable patient populations underpins their essential position in supportive care management. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/10708/enteral-medise-straw-market

Global Knee Bursitis Treatment Market Size & Forecast to 2034 According to a newly published market research report by 24LifeSciences, global knee bursitis treatment market was valued at USD 821.4 million in 2024 and is projected to reach USD 1.2 billion by 2031, growing at a compound annual growth rate (CAGR) of 5.1% during the forecast period 2024–2031. Knee bursitis involves the inflammation of the small fluid-filled sacs (bursae) that cushion the bones, tendons, and muscles around the knee joint. This painful condition, often developing from repetitive pressure, acute injury, or infection, significantly impairs mobility. Treatment typically combines rest, ice, anti-inflammatory medications, physical therapy, and in severe cases, corticosteroid injections or surgical intervention. The markets expansion reflects the critical need for effective solutions to manage pain and restore function for patients worldwide. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9087/knee-bursitis-treatment-market

Hydroxycarbamide Market’s CAGR of 6.1%: Leaders in Oncology & Hematology According to a newly published market research report by 24LifeSciences, global hydroxycarbamide market was valued at USD 226 million in 2025 and is projected to grow from USD 240 million in 2026 to reach USD 338 million by 2034, growing at a compound annual growth rate (CAGR) of 6.1% during the forecast period. Hydroxycarbamide, clinically known as hydroxyurea, is a foundational antineoplastic and antimetabolite medication that functions by inhibiting ribonucleotide reductase, a crucial enzyme for DNA synthesis. This mechanism positions it as a cornerstone therapy for several hematologic conditions. Its primary applications include the management of sickle cell disease, where it significantly reduces the frequency of painful crises and acute chest syndrome, as well as the treatment of specific cancers like chronic myelogenous leukemia, polycythemia vera, and essential thrombocythemia. Its established efficacy in cytoreduction and symptom management continues to underpin its critical importance in hematology and oncology. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/663/hydroxycarbamide-market-market

Pharmaceutical E-commerce Market Outlook 2026: Size, Trends & Key Players According to a newly published market research report by 24LifeSciences, global pharmaceutical e-commerce market is valued at USD 75.2 billion in 2026 and is projected to reach USD 185.5 billion by 2034, growing at a compound annual growth rate (CAGR) of 11.8% during the forecast period. Pharmaceutical e-commerce refers to the online sale and distribution of prescription medicines, over-the-counter (OTC) products, health supplements, and wellness items through digital platforms. This transformative channel facilitates transactions between pharmacies, distributors, and consumers via websites and mobile applications, encompassing both business-to-consumer (B2C) and business-to-business (B2B) models. The integration of telemedicine services for electronic prescription fulfillment is revolutionizing how patients access chronic and acute medications, offering unprecedented convenience and accessibility. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/10357/pharmaceutical-e-commerce-market

What Precision Medicine Expands Global 4-Fluorophenylacetic Acid Targeted Therapies? 4-Fluorophenylacetic acid serves as a critical building block in synthesizing various pharmaceuticals, agrochemicals, and advanced materials. Its unique molecular structure enables selective fluorination, which pharmaceutical companies leverage to enhance drug efficacy and metabolic stability. As regulatory pressures mount for safer, more effective medications, demand for this specialty intermediate continues its upward trajectory. Download FREE Sample Report: https://www.24chemicalresearch.com/download-sample/281887/global-fluorophenylacetic-acid-market-2024-261

Self-Administered Medication Market’s CAGR of 6.3%: Leaders Shaping Home Care According to a newly published market research report by 24LifeSciences, global self-administered medication market was valued at USD 185.6 billion in 2026 and is projected to reach USD 285.4 billion by 2034, growing at a compound annual growth rate (CAGR) of 6.3% during the forecast period. Self-administered medications encompass pharmaceutical products that patients can safely use without direct professional supervision, spanning various administration routes including oral tablets, subcutaneous injections, nasal sprays, and transdermal patches. This market represents a fundamental shift toward patient-centered healthcare, empowering individuals to manage chronic conditions like diabetes, rheumatoid arthritis, and hormone deficiencies conveniently at home. The growing acceptance of these therapies reflects broader trends in healthcare decentralization and patient autonomy. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8887/self-administered-medication-market

Global Generic Oncology Drugs Market Size & Growth Drivers Through 2034 According to a newly published market research report by 24LifeSciences, global generic oncology drugs market is valued at USD 35.2 billion in 2026 and is projected to reach USD 54.1 billion by 2034, growing at a compound annual growth rate (CAGR) of 6.3% during the forecast period. Generic oncology drugs are bioequivalent versions of brand-name cancer medications used after patent expirations, providing the same active ingredients, dosage, strength, and administration routes as their innovators. These drugs are broadly categorized into small molecule drugs and large molecule drugs (biosimilars), playing a critical role in making cancer treatment affordable and accessible globally. Their established efficacy and cost-effectiveness continue to underpin their importance in oncology care, particularly amid rising healthcare cost pressures. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8833/generic-oncology-drugs-market

Generic Oncology Drugs Market’s CAGR of 6.3%: Leading Companies to Watch in 2026 According to a newly published market research report by 24LifeSciences, global generic oncology drugs market is valued at USD 35.2 billion in 2026 and is projected to reach USD 54.1 billion by 2034, growing at a compound annual growth rate (CAGR) of 6.3% during the forecast period. Generic oncology drugs are bioequivalent versions of brand-name cancer medications used after patent expirations, providing the same active ingredients, dosage, strength, and administration routes as their innovators. These drugs are broadly categorized into small molecule drugs and large molecule drugs (biosimilars), playing a critical role in making cancer treatment affordable and accessible globally. Their established efficacy and cost-effectiveness continue to underpin their importance in oncology care, particularly amid rising healthcare cost pressures. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8833/generic-oncology-drugs-market

Non-Sterile Compounding Pharmacy Market Outlook 2025–2032: Size, Trends & Players According to a newly published market research report by 24LifeSciences, global non-sterile compounding pharmacy market is valued at USD 595 million in 2026 and is projected to reach USD 694 million by 2034, growing at a compound annual growth rate (CAGR) of 2.3% during the forecast period. Non-sterile compounding involves the customized preparation of medications for oral, topical, nasal, otic, or rectal administration, tailored to meet specific patient needs unavailable in commercial formulations. This practice requires strict adherence to regulatory standards like USP Chapter <795>, ensuring product integrity, accurate dosing, and patient safety. Its critical role in personalized medicine makes it indispensable for populations requiring unique formulations, including pediatric, geriatric, and patients with allergies or sensitivities to standard drug excipients. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9556/non-sterile-compounding-pharmacy-market

Top 10 Key Players Transforming the Global Hydroxyzine Imine Market (2026–2034) According to a newly published market research report by 24LifeSciences, global Hydroxyzine Imine market was valued at USD 797 million in 2026 and is projected to reach USD 1172 million by 2034, growing at a compound annual growth rate (CAGR) of 5.8% during the forecast period. Hydroxyzine Imine, a critical pharmaceutical intermediate, is the precursor in synthesizing hydroxyzine hydrochloride and hydroxyzine pamoate, which are first-generation antihistamines and central nervous system depressants. These final active pharmaceutical ingredients (APIs) are essential for medications primarily indicated to manage anxiety and provide symptomatic relief from pruritus (itching) due to allergic conditions like chronic urticaria and atopic dermatitis. Its established role in allergy and anxiety management continues to underpin its significance in both dermatology and psychiatric therapeutic areas. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9259/hydroxyzine-imine-market

Next-Gen Therapies Redefining the Eye Infections Treatment Market According to a newly published market research report by 24LifeSciences, global eye infections treatment market value is at USD 10.8 billion in 2026 and is projected to reach USD 15.6 billion by 2034, growing at a compound annual growth rate (CAGR) of 4.7% during the forecast period. Eye infections represent a critical segment of ophthalmic care, encompassing conditions like conjunctivitis, keratitis, blepharitis, and endophthalmitis caused by bacterial, viral, fungal, or parasitic pathogens. The market comprises diverse treatment modalities including antibiotic drops, antiviral ointments, antifungal creams, and oral medications administered across hospital, clinic, and retail settings. The sector's growth is underpinned by increasing global incidence rates, particularly for bacterial conjunctivitis which affects approximately 6 million Americans annually, driving continuous demand for effective therapeutic solutions. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9139/eye-infections-treatment-market

How Novel Drug Classes Are Redefining the Neuropathic Pain Drugs Market According to a newly published market research report by 24LifeSciences, the global neuropathic pain drugs market was valued at USD 6.2 billion in 2024 and is projected to reach USD 8.9 billion by 2031, growing at a compound annual growth rate (CAGR) of 5.3% during the forecast period 2025–2031. Neuropathic pain drugs are a class of pharmaceuticals specifically developed to manage pain arising from damage or disease affecting the somatosensory nervous system. This type of pain, which is often chronic and debilitating, can manifest as burning, shooting, or stabbing sensations, and includes conditions like allodynia (pain from non-painful stimuli) and dysesthesia (abnormal unpleasant sensations). These medications include various drug classes such as anticonvulsants, antidepressants (like SNRIs and TCAs), topical agents, and other analgesics, targeting the complex mechanisms behind nerve-related pain. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8942/neuropathic-pain-drugs-market